Topic Listing for CuraGen

Ability Repurchase Notes Required Cash Change Control Fundamental Acceleration
Access Information Accrued Expenses
Accrued Prepaid Expenses Action Consent
Action Respect Securities Other Corporations Action Without Meeting
Additional Agreements Additional Fees Executive Chairman Board
Additional Information Celldex-curagen Merger Find Additional Information Find
Additional Information Transaction Find Address Principal Executive Offices Zip Code
Adjustments Changes Common Stock Certain Other Events Adjustments Reorganization Event
Administration Administration Delegation
Advanced Oncology Pipeline Update Adverse Events
Aggregate Purchase Price Payable Curagen Stockholders Merger Subject Aggregated Option Exercises Last End Values
Agreement Agreement Plan Merger
Allocation Alterations Improvements
Amended Restated Employment Agreement Timothy Shannon Amendment
Amendment David Wurzers Employment Agreement Amendment Lease Agreement
Amendment License Supply Distribution Agreement Amendment No1
Amendment No2 Amendment Termination
Amendments Amendments Articles Incorporation Bylaws Changes
Amgen Freemont Inc Formerly Abgenix Amgen Fremont
Amgen Fremont Formerly Abgenix Annual Compensation
Annual Meeting Annual Meetings Stockholders
Annual Report Form 10-k Approval 2007 Stock Incentive Plan
Approval Amendment 2007 Stock Incentive Plan Increase Maximum Arbitration
Asco 2008 Annual Meeting Chicago Assignment
Assignment Patents Assignment Subletting
Assurances Pending Merger Between Curagen Celldex Consummated Failure Attachment Regulatory History
Audit Committee Audit Committee Board Directors
Audit Committee Report Audits
Authorizations Authorized Capital Stock
Available Information B-1
B-2 B-3
Background Oral Mucositis Velafermin Cg53135 Background Velafermin
Base Salary Basis Presentation Business Overview
Basis Presentation Reclassifications Bay 76-7171 Formerly Ct052 Type Diabetes
Bay 76-7171 Type Diabetes Bayer
Bayer Metabolic Disease Collaboration Because Business Strategy Still Largely Untested Not Know
Because Clinical Trials Products Expensive Protracted Outcome Uncertain Because Early Stages Drug Development Not Know Whether
Because Limited Experience Developing Commercializing Marketing Products Unsuccessful Because Neither Nor Collaborative Partners Received Marketing Approval
Belinostat Combination Carboplatin Paclitaxel Against Bladder Cancer Belinostat Combination Carboplatin Paclitaxel Against Ovarian Cancer
Belinostat Combination Idarubicin Against Acute Myelogenous Leukemia Aml Belinostat Combination Velcade Bortezomib Injection Against Multiple Myeloma
Belinostat Pxd101 Histone Deacetylase Hdac Inhibitor Being Investigated Belinostat Pxd101 Treatment Cancer
Belinostat Treatment Cancer Beneficial Ownership Reporting Compliance
Benefits Benefits Termination
Board Compensation Policies Board Determination Independence
Board Directors Board Meetings Attendance
Bond Bonuses Restricted Stock Awards Option Grants Executive Officers
Bonuses Stock Option Grants Executive Officers Branford Conn 2006 Curagen Corporation Nasdaq Crgn Today
Branford Conn 2007 Curagen Corporation Nasdaq Crgn Today Branford Conn 2008 Curagen Corporation Nasdaq Crgn Today
Breast Cancer Broker
Business Substantial Risk Product Liability Claims Unable Obtain Cannot Certain Security Measures Protect Confidential Information Proprietary
Cannot Certain Security Measures Protect Proprietary Technologies Capital Leases
Capitalization Subsidiaries Cash Compensation Hoc Committee Fees
Cash Compensation Meeting Fees Cash Compensation Retainers
Cash Compensation-retainers Cautionary Regarding Forward-looking Statements
Cautionary Statements Celldex Contacts
Celldex Merger Celldex Not Achieve Benefits Expect Merger Material Adverse
Celldex Therapeutics Inc Certain Additional Agreements
Certain Factors Affect Results Operations Certain Matters Pertaining Stockholder Business Nominations
Certain Relationships Related Transactions Certain Rules Interpretation Agreement Schedules
Certificate Incorporation Curagen Corporation Certificates Stock
Certification Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Certifications 302 Cg53135
Cg53135 Oncology Support Cg53135 Protein Therapeutic Prevention Treatment Oral Mucositis
Chairman Chairman Board
Change Control Changes Control Registrant
Changes Internal Controls Changes Level Government Funding Life Sciences Research Affect
Chief Executive Officer Chief Executive Officer Compensation
Clinical Development Plan Clinical Development Program
Clinical Products Clinical Trial Processes
Clinical Trials Drug Candidates Prolonged Delayed Unable Commercialize Cln-4 Phase Trial Evaluating Intravenous Belinostat Combination 5-fluorouracil
Cln-6 Phase Trial Evaluating Intravenous Belinostat T-cell Lymphomas Cln-8 Phase Trial Evaluating Intravenous Belinostat Combination Paclitaxel
Code Ethics Corporate Conduct Collaboration Agreement
Collaboration Goal Collaboration Revenue
Collaborations Collaborative Partner Terminates Fails Perform Obligations Agreements Development
Commencement Term Employment Committees
Committees Board Directors Common Stock
Common Stock Delisted Nasdaq Global Market Price Continues Communicating Independent Directors
Compared 2005 Comparison Cumulative Total Return Among Curagen Corporation Nasdaq
Compensation Compensation Board Directors
Compensation Committee Compensation Committee Board Directors
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Directors Compensation Program Objectives Philosophy
Competition Competition Field Intense Likely Increase
Completion 454 Acquisition Completion 454 Sale
Completion Acquisition Disposition Assets Completion Mid 2006
Compliance Government Regulation Critical Business Failure Satisfy Regulatory Compliance Internal Revenue Service 162
Components Executive Compensation Program Comprehensive Loss
Condemnation Conditions Merger
Conduct Business Conference Call Details
Conference Call Details Dial-in Information Conference Call Held Today 1100
Conference Call Hosted Today 900 Edt Conference Call Information
Conference Call Scheduled Friday 2009 830 Et- Conference Call Today 1100 Eastern Time
Conference Call Webcast Details Confidentiality
Confidentiality Publication Consent Independent Registered Public Accounting Firm
Consent Spouse Constituent Corporations
Contact Contacts
Contract Index Contracts
Contractual Obligations Controls Procedures
Convertible Debt Service Obligations Prevent Taking Actions Otherwise Convertible Subordinated Debentures Due 2007
Corporate Governance Guidelines Corporate Restructuring
Corporate Seal Covenant Not Compete
Covenants Cr002
Cr002 Fully Human Monoclonal Antibody Treatment Iga Nephropathy Cr002 Fully-human Monoclonal Antibody Treatment Kidney Inflammation
Cr002 Kidney Inflammation Cr011
Cr011 Antibody-drug Conjugate Being Investigated Metastatic Melanoma Cr011 Fully Human Monoclonal Antibody-drug Conjugate Treatment Metastatic
Cr011 Treatment Cancer Cr011-vcmmae Clinical Development Program
Cr011-vcmmae Phase Trial Treatment Metastatic Melanoma Cr011-vcmmae Treatment Cancer
Cr012 Treatment Cancer Cr014 Treatment Cancer
Cr014-vcmmae Treatment Cancer Critical Accounting Policies Estimates
Ct052 Ct052 Orally Administered Small Molecule Drug Management Adult-onset
Curagen Curagen Abx Research Plan
Curagen Announces Appointment Board Directors Curagen Announces Executive Management Changes
Curagen Announces Preliminary Top-line Phase Results Velafermin Curagen Announces Pricing Common Stock Offering
Curagen Appoints Frank Armstrong Chief Executive Officer Curagen Appoints Paul Finigan Senior Vice President General
Curagen Commercialization License Curagen Contact
Curagen Contacts Curagen Corporation
Curagen Corporation Executive Incentive Plan Curagen Corporation Lock-up Agreement
Curagen Corporation Receives Notification Nasdaq Curagen Corporation Subsidiary
Curagen Corporation Table Contents Curagen Pipeline Update
Curagen Reports 2005 Results Curagen Reports 2006 Financial Results
Curagen Reports 2006 Results Curagen Reports 2007 Financial Results
Curagen Repurchases 399 Outstanding 2007 Convertible Debt Curagen Repurchases Additional 239 Outstanding 2007 Convertible Debt
Curagen Subject Business Uncertainties Contractual Restrictions While Merger Curagen Topotarget Sponsored Clinical Trials Pxd101
Curagen Upcoming Presentations Curagen-sponsored Belinostat Clinical Development Program
Curagens Projected Milestones Damage Destruction
Dated 2004 Debt Investments Impacted Financial Viability Underlying Companies
Debt Investments Impacted Financial Viability Underlying Companies Assets Debt Service Obligations Adversely Affect Cash Flow
Default Deficiency Earnings Available Cover Fixed Charges
Deliveries Deloitte Touche Llp
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Depend Ability License Technologies Depend Academic Collaborators Consultants Scientific Advisors
Depend Attracting Retaining Key Employees Depend Limited Number Suppliers Manufacture Supply Critical Components
Designated Antigens Exclusive Development Commercialization Manufacturing
Development Milestone Payments Curagen Development Status
Diabetes Direct Indemnity
Directions Principal Offices Director Attendance Annual Meeting Stockholders
Director Compensation Director Independence
Director Nomination Process Director Officer Liability
Director Term Expiring 2009 Annual Meeting Class Directors
Directors Terms Expiring 2006 Annual Meeting Class Directors Terms Expiring 2007 Annual Meeting Class
Directors Terms Expiring 2008 Annual Meeting Class Directors Terms Expiring 2009 Annual Meeting Class
Directors Terms Expiring 2010 Annual Meeting Class Directors Terms Expiring 2011 Annual Meeting Class
Disability Death Disagreements Regarding Closing Statement
Disclaimer Limitation Liability Indemnification Discretion Proxies Authorized Vote Such Other Matters Properly
Discretionary Cash Bonus Option Awards Stock Discretionary Cash Bonuses
Disease Focus Dividends
Documents Incorporated Reference Drug Candidates Still Development Remain Subject Clinical Testing
Drug Candidates Still Early Stages Development Remain Subject Drug Development Approach
Earlier Stage Assets Earnings Deficiency Available Cover Fixed Charges
East Main Street Effect Expiration Termination
Effect Future Repurchases Convertible Debentures Due 2011 Adversely Effect Termination
Eip Equity Incentive Award Eip Non-equity Incentive Award
Either Election
Election Directors Nominees Not Available Such Substitute Board Eligibility
Eligibility Receive Awards Eligible Antigen Criteria
Employee Advised She Twenty-one Calendar Consider Agreement General Employee Benefit Plans
Employee Freely Knowingly After Due Consideration Enters Agreement Employee Matters
Employee Name Employee Party Declaration
Employees Employment Agreement Sean Cassidy
Employment Agreements Employment Agreements Executive Officers
Employment Agreements Termination Change Control Arrangements Employment Duties Responsibilities
Enforcement Sgi Patents Engage Acquisitions Unsuccessful
Entire Agreement Amendment Entry Material Definitive Agreement
Enumeration Environmental Compliance Indemnifications
Equity Awards Policies Practices Equity Compensation Plan Information
Estimated Open Payables Estimated Prepaid Expenses
Estoppel Certificate Evaluation Disclosure Controls Procedures
Even Obtain Regulatory Approvals Drug Candidates Subject Ongoing Exact Name Registrant Specified Charter
Except Per Share Data Except Share Data
Exchange Certificates Execution Copy
Executive Director Compensation Processes Executive Incentive Plan
Executive Officer Compensation Program Executive Officer Compensation Summary
Executive Officers Exemption Liability
Exhibits Exhibits Reports Form 8-k
Existing Sgi Technology Expected 2006-
Expedited Review Approval Expenses
Explanatory Extinguishment Debt
Facsimile Signatures Fair Value Measurements Recurring Basis 2008
Fair Value Measurements Recurring Basis 2009 Federal Income Tax Consequences
Fees Royalties Payments Financial Guidance 2007
Financial Statement Schedules Financial Statements
Financial Statements Exhibits Following New Shall Added Original Agreement
Force Majeure Foreign Regulation
Foreseeable Future 454 Rely Single Distributor Roche Generate Foreseeable Future Rely Single Distributor Roche Generate Most
Foreseeable Future Rely Single Distributor Roche Generate Product Form 10-k
Form 10-q Form Opinion Mintz Levin Cohn Ferris Glovsky Popeo
Form Registered Shares Form Three-way Mta
Form Two-way Mta Form Unregistered Shares
Former Name Address Changed Since Last Report Forward-looking Statements
Fractional Shares Adjustments Fringe Benefits
Fringe Benefits Vacation Future Liquidity
Future Liquidity Event Proposed Merger Celldex Not Completed General
General Administrative Expenses General Compensation Philosophy
General Powers Number Election Tenure Qualification General Provisions Applicable Awards
Genome Sequencer System Genome Sequencer Systems
Government Other Third-party Payors Fail Provide Coverage Adequate Government Regulation Product Approval
Grant Additional Stock Options Grant Options Appointment
Grant Revenue Granted 2007 Stock Incentive Plan
Grants Plan-based Awards Guidance 2007
Guidance Financial Outlook Guidance Oncology Pipeline Milestones
History History Operating Losses Expect Incur Foreseeable Future Not
History Operating Losses Expect Incur Future History Operating Losses Expect Incur Future Not Meaningful
Holding Over Host Conference Call Today 1100
Householding Annual Meeting Materials Human Monoclonal Antibody Therapeutics
Immediate Release Immediate Release 2009
Important Additional Information Filed Sec Improvements New Technologies
Incentive Stock Options Income Tax Benefit Provision
Income Taxes Indemnification
Indemnification Advancement Expenses Indemnification Employees Agents Corporation
Index Index Schedules Exhibits
Inflammatory Diseases Infocelldextherapeuticscom
Information Contact Infringe Intellectual Property Rights Others Required Obtain License
Infringement Actions Brought Parties Infringes Alleged Infringe Intellectual Property Rights Parties
Initial Clinical Development Program Pxd101 Injunctive Relief
Inspection Landlord Instrument Reagent Sales Royalties
Insurance Intellectual Property
Interest Expense Interest Income Net
Interests Related Persons 454 Sale Interoffice Memorandum
Interpretation Inventory
Investment Valuation Issuance Patents Not Provide Sufficient Protection
Jonathan Rothberg Step Down Chief Executive Officer Curagen Jsc Governance Development Program
Jurisdiction Lab Notebooks Contained Experiments Relating Belinostat Other Curagen
Landlord Landlords Consent Novation
Landlords Repairs Landlords Right Perform Tenants Covenants
Landlords Rules Regulations Large Amount Convertible Debt Service Obligations Prevent Taking
Large Amount Debt Service Obligations Prevent Taking Actions Lease Agreement
Legal Proceedings Level Inputs
Liable Failure Comply Hazardous Product Regulations License Supply Distribution Agreement
Licensed Products Specifications Licenses Option Dropped Antigens
Liens Life Sciences
Life Sciences Corporation Life Sciences Outlook Highlights
Life Sciences Receive Roche Achieving Commercialization Milestone Life Sciences Receives 115 Milestones Roche
Life Sciences Roche Announce Commercial Launch Genome Sequencer Life Sciences Technology Platform Development Initial Stages
Life Sciences Upcoming Product Releases Life Sciences Update
Likely Need Raise Additional Funding Not Available Favorable Limitation Liability
Limitation Repricing Limitations Audit Committees Role
Limited History Manufacturing Instrument Systems Consumable Products Success Liquidity Capital Resources
List Schedules Exhibits Long Term Incentives
Long Wharf Drive Floor New Haven Connecticut 06511 Long-term Incentive Compensation
Loss Per Share Lost Stolen Destroyed Certificates
Managements Report Internal Control Over Financial Reporting Manufacturing Responsibility
Manufacturing Upgrade Performance Overview Map Directions Omni New Haven Hotel Yale
Market Information Market Perception Merger Negative Stock Price Decline Become
Market Price Common Stock Highly Volatile Market Price Topotarget Common Stock Highly Volatile
Material Modification Rights Security Holders Meetings
Meetings Committees Board Directors Meetings Stockholders
Melanoma Membership
Memorandum Memorandum Understanding
Merger Milestone Revenue
Milestones Financial Guidance Minority Interest Subsidiary
Miscellaneous Multiple Myeloma
Mutual Research Licenses Name Person Filing Proxy Statement Other Registrant
Named Executive Officers 2006 Base Salaries Bonus Targets Nci P7267 Phase Trial Evaluating Intravenous Belinostat Monotherapy
Nci-sponsored Belinostat Clinical Development Program Nci-sponsored Clinical Trials Pxd101
Nda Bla Approval Processes Need Raise Additional Funding Not Available Favorable Terms
Needham Branford 2009 Needham Mass 2009
New Haven Conn 2005 Curagen Corporation Nasdaq Crgn New Haven Connecticut 06511
Nominating Governance Committee Nominating Governance Committee Board Directors
Nominees Re-election Annual Meeting Class Non-employee Director Compensation Summary
Non-exclusivity Rights Non-gaap Financial Measures
Non-reliance Previously Issued Financial Statements Related Audit Non-statutory Stock Options
Not Comply Laws Regulating Protection Environment Health Human Not Ensure Existing Cash Investment Balances Sufficient Meet
Not Obtain Adequate Intellectual Property Protection Able Prevent Notes Editors
Notice Annual Meeting Shareholders Held 2005 Notice Hereby Given
Notice Lease Notice Meetings
Notice Regarding Certain Options Granted Curagen Corporation Delaware Notices
Number 000-23223 Obligations Parties
Obtains Key Components Single Source Limited Group Suppliers Officers
Oncology Oncology Pipeline Milestones
Oncology Pipeline Update Operating Leases
Option Exercises Stock Vested Option Grants Last
Option Renew Option Terminate
Oral Mucositis 2006 Bmt Tandem Meetings Organization
Orphan Drug Other
Other Business Other Events
Other Information Other Matters
Other Stock-based Awards Overview
Ownership Inventions Technology Data Paragraph Deleted Entirety Replaced
Parking Part
Part Other Information Participants Solicitation
Participation Meetings Conference Telephone Party Agreements
Party Royalties Adjustments Party Successfully Asserts 454 Infringed Patents Business Adversely
Past Awards 2007 Plan Patent Applications
Patent Applications Not Result Issued Patents Then Competitors Patent Enforcement
Patent Prosecution Maintenance Patents Copyrights Intellectual Property
Patents Licenses Patents Not Provide Sufficient Protection 454 Technology
Paul Finigan Payment Fees Reimbursement Travel Other Expenses
Payments Books Records Pediatric Exclusivity
Performance Graph Perquisites
Phase Monotherapy Results Intravenous Belinostat Phase Programs Oncology Fast Track Status Cg53135 Highlight
Phase Results Intravenous Belinostat Combination Phase Results Oral Belinostat
Phase Trial Evaluating Role Pxd101 Treatment Multiple Myeloma Phase Trial Pxd101 Combination 5-fluorouracil 5-fu Advanced Solid
Phase Trial Pxd101 Combination Paclitaxel Carboplatin Advanced Solid Phase Trial Pxd101 Monotherapy Combination Dexamethasone Advanced Multiple
Phase Trial Results Treatment Breast Cancer Phase Trial Results Treatment Metastatic Melanoma Cancer
Phase Trial Results Treatment Multiple Myeloma Phase Trial Results Treatment Ovarian Cancer
Phase Trial Results Treatment T-cell Lymphoma Physicians Patients Third-party Payors Not Accept Future Drugs
Pipeline Plan Benefits
Please Date Sign Return Proxy Card Earliest Convenience Please Votes Example
Policies Procedures Related Person Transactions Portion 454s Sales International Customers Subject Risks
Portions Omitted Been Filed Separately Secretary Pursuant Application Post-approval Requirements
Potential Post-employment Payments Table Powers
Pre-approval Policy Audit Committee Preclinical Clinical Therapeutics
Preliminary Statements Premises
President Press Release Contain Forward-looking Statements Including Expectation Initiate
Principal Accountant Fees Services Principal Accounting Fees Services
Principles Jsc Management Development Program Proceeds Receive Merger Less Anticipated Due Higher Expected
Proceeds Receive Sale Stake 454 Less Anticipated Due Product Documentation Packaging Labeling Steering Committee
Product Revenue Product Technical Information
Project Descriptions Project List
Pronouns Proposal One-election Directors
Proposal Two-approval 2007 Stock Incentive Plan Proposed Merger Celldex
Proprietary Trade Secret Information Protein Therapeutics
Provisions Foreign Participants Proxies Voting
Proxy Being Solicited Board Directors Curagen Corporation Proxy Statement
Proxy Statement 2007 Annual Report Stockholders Available Viewing Proxy Statement 2008 Annual Report Stockholders Available Viewing
Proxy Statement Annual Meeting Shareholders Proxy Statement Pursuant Securities Exchange Act 1934
Purpose Purpose Agreement Definitions
Pursuant Internal Revenue Code 1986 Amended Pursuant Requirements Securities Exchange Act 1934 Registrant Duly
Pursuant Requirements Securities Exchange Act 1934 Report Been Pxd101
Pxd101 Clinical Development Program Pxd101 Oncology
Pxd101 Small Molecule Histone Deacetylase Hdac Inhibitor Treatment Pxd101 Treatment Cancer
Pxd118490 Qualification
Quantitative Qualitative Disclosures Market Risk Quarterly Operating Results Fluctuated Greatly Continue
Quarterly Period 2004 Quorum
Recent Pipeline Highlights Recently Enacted Pronouncements
Recitals Record Date
Records Registrants Telephone Number Including Area Code 203 401-3330
Registrants Telephone Number Including Area Code 203 481-1104 Regular Meetings
Regulation Disclosure Regulations
Regulatory Assistance Regulatory Matters Product Quality Insurance
Reimbursement Release Agreement
Release Claims Release Contains
Reliance Books Reports Records Rely Parties Conduct Clinical Trials Provide Other Services
Rely Significantly Collaborative Partners Business Harmed Unable Maintain Rely Significantly Collaborative Partners Gain Access Specified Technologies
Remainder Page Intentionally Left Blank Rent
Report Audit Committee Report Compensation Committee
Report Independent Registered Public Accounting Firm Reporting
Reporting Responsibilities Reports Exchange Rates
Reports Financial Statements Cash Representations Warranties
Representations Warranties Buyer Transitory Subsidiary Representations Warranties Curagen
Representations Warranties Topotarget Request Special Protocol Assessment
Request Special Protocol Assessment Clinical Requisite Buyer Stockholder Vote Means Majority Total Votes
Research Antigen Designation Research Development
Research Development Agreement Research Development Expenses
Research Program Research Support
Reservation Ownership Resignation Removal
Restatement Financial Statements Restricted Stock
Restricted Stock Agreement Restricted Stock Awards
Restricted Stock Units Restrictive Covenants Indentures Relating Ability Incur Future Indebtedness
Restructuring Related Charges Results Operations Financial Condition
Results Phase Melanoma Trial Expected Revenue Recognition
Right Advancement Expenses Right Indemnification
Right Indemnitees Bring Suit Rights Landlord Non-waiver
Rights Sublicense Risk Factors
Risks Related Business Risks Related Financial Results
Roche Diagnostics Roche Training Staff
Royalties Royalties Payable Sgi
Rules Safe Harbor
Safe Harbor Forward-looking Statements Sale 454 Life Sciences Corporation
Sarbanes-oxley Act 2002 Scassidycuragencom
Schedule 14a Schedule 14a Information
Schedule Exhibits Sean Cassidy
Seasonality Seattle Genetics
Seattle Genetics Inc Collaboration Agreement Secretary Assistant Secretaries
Securities Exchange Act 1934 Securities Issue Fund Operations Cause Dilution Shareholders Ownership
Securities Issue Fund Operations Cause Dilution Stockholders Ownership Securities Registered Pursuant Act
Security Deposit See Reverse Side
Selected Balance Sheet Information Separation Agreement Elizabeth Whayland
Separation Agreements Sequencing Center
Sequencing Service Revenue Service Engineers
Services Severability
Severance Change Control Benefits Sgi In-licenses
Shall Amended Time Controlled Sgi Accordance Compliance In-licenses Shareholder Proposals Nominations Director
Shares Available Awards Shipment
Short Term Incentives Sign-on Payments
Signature Signatures
Significant Leverage Result Issuances Debt 2000 2004 Significant Leverage Result Sale Debt 2004
Significant Leverage Result Sales Debt 2000 2004 Significant Leverage Result Sales Debt 2004
Significant Recent Developments Small Molecule Therapeutics
Solicitation Special Meetings
Special Meetings Stockholders State
Statement Real Property Interest Status Stock
Stock Appreciation Rights Stock Available Awards
Stock Compensation Stock Incentive Plan
Stock List Stock Options
Stock Plan Stock-based Compensation
Stockholder Meetings Joint Proxy Statement Prospectus Stockholder Proposals Nominations Director
Stockholder Rights Plan Stockholders
Strategic Collaborations Strategy
Subject Claims Infringing Patents Other Intellectual Property Rights Subject Competition Organizations Developed Developing Technologies Products Service
Subject Matter Dmf 2006-008 Type Pxd101 Change Ownership Subject Matter Dmf 2006-009 Type Pxd101 Injection Change
Sublicensing Curagen Submission Matters Vote Security Holders
Subordination Subsections 1350 Chapter Title United States Code
Subsidiaries Subsidiaries Registrant
Substantially Gross Consolidated Revenue 2006 Earlier Was Derived Substantially Gross Consolidated Revenue 2006 Was Derived Sales
Substitute Options Summary
Summary Compensation Table Supplement Proxy Statement Annual Meeting Held 2005
Supplement Proxy Statement Annual Meeting Held 2006 Supply Chain Logistics Overview
Surreneder Premises Survival Indemnification
Table Contents Take Fee
Targets Non-equity Equity Incentives Executive Officers Tax Consequences
Tax Considerations Tax Matters
Taxes Fees Technology
Technology Disclosure Technology Platform Development Initial Stages Commercialization
Tenant Tenant Improvements
Tenants Property Tenants Repairs
Tenure Removal Term
Term Agreement Term Employment
Term Termination Termination
Termination Amendment Termination Fee
Termination Velafermin Development Program Third-party Payors Not Adequately Reimburse Customers Product Candidates
Time Exceed Federal Deposit Insurance Corporation Limits Bank Time Periods
Timothy Shannon Title Class
Topotarget Topotarget Logo Address
Topotargets Development Collaboration Products Training Concept
Transaction Terms Transactions Interested Parties
Transferability Awards Transfers Stock
Transition Services Agreement Transition Severance Agreement Frank Armstrong
Treasurer Assistant Treasurers Treatment Options
Types Awards Ultra High-throughput Genome Sequencing System
Unable Establish Sales Marketing Capabilities Enter Agreements Parties Unable Manufacture Obtain Sufficient Quantities Products Ensure Proper
Unable Obtain Foreign Regulatory Approval Commercialize Drug Candidates Uncertain Whether 454 Able Successfully Develop Commercialize New
Uncertain Whether Able Successfully Develop Commercialize New Products Undertakings Parties
United States United States Government Regulation
Unregistered Sales Equity Securities Proceeds Upcoming Curagen Presentations
Upcoming Oncology Pipeline Milestones Upcoming Presentations 454 Life Sciences
Upcoming Presentations Curagen Update 2006 Guidance
Update 2007 Guidance Financial Outlook Update 454 Life Sciences
Update Curagen Subsidiary 454 Life Sciences Update Pxd101
Updated Guidance 2005 Utilities Fuel
Vacancies Newly Created Directorships Velafermin C-421 Phase Study Details
Velafermin Cancer Supportive Care Velafermin Cg53135
Velafermin Formerly Cg53135 Cancer Supportive Care Velafermin Phase Safety Results Treatment
Velafermin Prevention Severe Oral Mucositis Velafermin Protein Therapeutic Being Investigated Prevention Severe Oral
Velafermin Protein Therapeutic Prevention Treatment Oral Mucositis Version
Vice Presidents Waiver Notice
Warranty Waste
Witnesseth Wwwcelldextherapeuticscom
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki